Guillain-Barré Syndrome: Autoimmune Neuropathy Causing Ascending Paralysis
Guillain-Barré Syndrome (GBS) is an acute autoimmune polyradiculoneuropathy triggered by molecular mimicry after infection.
Epidemiology & Triggers
- Incidence: 1–2/100,000/year; slight male predominance.
- Preceding infection (1–4 weeks prior): Campylobacter jejuni (30%), CMV, EBV, Mycoplasma, Zika, influenza, SARS-CoV-2.
- Rare post-vaccination (e.g., 1976 swine flu; COVID vaccines – very rare, benefit outweighs risk).
Clinical Course
- Ascending weakness: Starts in legs → arms → cranial nerves (facial diplegia common).
- Areflexia/hyporeflexia early sign.
- Autonomic instability: BP lability, arrhythmias, ileus, urinary retention.
- Respiratory failure: 20–30% require mechanical ventilation.
- Nadir at 2–4 weeks; recovery over months to years.
Diagnosis
- Clinical + albuminocytologic dissociation (CSF: high protein, normal WBC) – appears week 2.
- Nerve conduction studies: demyelinating (AIDP) vs. axonal (AMAN/AMSAN) variants.
- Anti-ganglioside antibodies (GM1, GD1a, GQ1b – Miller Fisher variant).
Treatment
- IVIG 2 g/kg over 5 days or Plasma exchange (5 exchanges) – equally effective; start within 2 weeks.
- Supportive: ICU monitoring, DVT prophylaxis, pain management (gabapentin), rehab.
Prognosis
- 70% full recovery; 15–20% residual weakness; 3–5% mortality (despite treatment).
- Poor predictors: age >60, severe initial weakness, axonal variant, delayed treatment.
Brain & Nervous System - Related Articles
- Botox Side Effects: Understanding Systemic Risks & Risks
- Auditory Neuropathy: Understanding the Condition & Its Impact
- Understanding Sudden Changes in Men's Behavior: Potential Health Concerns
- How the Skeletal System Protects the Brain & Heart
- Neural Tube Formation in Mammalian Embryos: From Ectoderm Folding to Brain and Spinal Cord, and Defect Prevention
- CIWA Assessment: Understanding Alcohol Withdrawal Protocols
- Essential Skills for Neurologists: Clinical, Cognitive & Interpersonal Competencies
